Cerus Corporation

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development.
Company Growth (employees)
Concord, US
Size (employees)
204 (est)+16%
Cerus Corporation is headquartered in Concord, US

Key People at Cerus Corporation

William M. Greenman

William M. Greenman

President and CEO
Kevin D. Green

Kevin D. Green

VP, Finance & CFO
Laurence M. Corash

Laurence M. Corash


Cerus Corporation Office Locations

Cerus Corporation has offices in Concord and Amersfoort
Concord, US (HQ)
2550 Stanwell Dr
Amersfoort, NL
79 Stationsstraat

Cerus Corporation Data and Metrics

Cerus Corporation Financial Metrics

Cerus Corporation's revenue was reported to be $39.3 m in FY, 2016 which is a 15% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

39.3 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

19 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(62.9 m)

EBIT (FY, 2016)

(61.4 m)

Market capitalization (24-May-2017)

234.9 m

Closing share price (24-May-2017)


Cash (31-Dec-2016)

22.6 m


231.7 m
Cerus Corporation's current market capitalization is $234.9 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


39.7 m36.4 m34.2 m39.3 m

Revenue growth, %


Cost of goods sold

22.6 m21.2 m23.5 m20.3 m

Gross profit

17.1 m15.2 m10.8 m19 m

Gross profit Margin, %


Operating expense total

45.4 m59.7 m71.8 m80.4 m


(28.3 m)(44.5 m)(61.1 m)(61.4 m)

EBIT margin, %


Interest expense

(332 k)(599 k)(1.7 m)(2.4 m)

Pre tax profit

(43.1 m)(38.6 m)(59.5 m)(62.7 m)

Income tax expense

218 k195 k(3.7 m)175 k

Net Income

(43.3 m)(38.8 m)(55.9 m)(62.9 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


29.5 m22.8 m71 m22.6 m

Accounts Receivable

6.1 m5.5 m5.8 m6.9 m


13.1 m15 m10.8 m12.5 m

Current Assets

78.2 m74.9 m130.4 m94.1 m


2.2 m3.8 m3.5 m3 m


1.3 m1.3 m1.3 m1.3 m

Total Assets

83.4 m81.8 m139.5 m103.5 m

Accounts Payable

5.7 m9.9 m5.2 m8.6 m

Total Debt

3.4 m9.9 m19.8 m19.4 m

Current Liabilities

39.4 m29.2 m21.9 m26.9 m

Additional Paid-in Capital

545.9 m583.4 m685.2 m718.3 m

Retained Earnings

(503.2 m)(541.9 m)(597.8 m)(660.7 m)

Total Equity

42.8 m41.5 m94.8 m57.8 m

Debt to Equity Ratio

0.1 x0.2 x0.2 x0.3 x

Debt to Assets Ratio

0 x0.1 x0.1 x0.2 x

Financial Leverage

1.9 x2 x1.5 x1.8 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(43.3 m)(38.8 m)(55.9 m)(62.9 m)

Depreciation and Amortization

202 k202 k202 k202 m

Accounts Receivable

(1.7 m)632 k(301 k)(1.1 m)


(1.8 m)3 m4 m(1.8 m)

Accounts Payable

(1.5 m)(973 k)(3.9 m)3.3 m

Cash From Operating Activities

(26.8 m)(39.8 m)(51.1 m)(53.5 m)

Capital Expenditures

(663 k)(2.1 m)(722 k)(563 k)

Cash From Investing Activities

(29.1 m)(3.3 m)1.4 m(19.9 m)

Long-term Borrowings

(7.6 m)(3.5 m)(113 k)(622 k)

Cash From Financing Activities

58.6 m36.5 m98 m24.6 m

Interest Paid

294 k563 k1.1 m1.4 m

Income Taxes Paid

146 k177 k153 k157 k

Free Cash Flow

(27.5 m)(41.9 m)(51.9 m)(54.1 m)
Y, 2016


-3.8 x


-4.3 x


-4.3 x


0.3 x


0.2 x

Financial Leverage

1.8 x

Cerus Corporation Operating Metrics

FY, 2016

Patents Issued


Cerus Corporation Market Value History

Cerus Corporation Company Life and Culture

You may also be interested in